Fundamentos: Dados recentes de metanálise tem levantado dúvidas com relação a segurança dos stents eluidores de fármacos com polímero biodegradável (BP-DES) quando comparados aos stents eluidores de fármacos com polímero durável (DP-EES). O NOBORI® Biolimus-Eluting Stent (BP-BES) versus XIENCE® / PROMUS® (DP-DES) Everolimus-Eluting Stent Trial (NEXT Trial) é um estudo randomizado de 98 centros, realizado...
EVOLVE II TRIAL: SYNERGY everolimus-eluting stent is not inferior to Promus Element
Dean J. Kereiakes2014-11-20
Reduction of ischemic events after 30 months of prasugrel following TAXUS stent implantation
Article The TAXUS Liberté Post Approval study included patients treated with TAXUS paclitaxel DES receiving prasugrel for 12 to 30 months. Primary end point was a combination of death, infarction or stroke that resulted in 3.7% after 30 months vs. 8.8% after 12 months of prasugrel administration (p<0.001). Death and stroke rates were similar between...
BIOSCIENCE study: Absorbable polymer versus permanent in sirolimus-eluting stents
This multicenter study randomized 1063 patients to receive the sirolimus-eluting stent with absorbable polymer and 1056 patients to permanent polymer stent. No differences in stent thrombosis (3.4% in the group with permanent polymer versus 2.8% in the group with absorbable polymer), target vessel revascularization (6.7% for both) or mortality (2.1% versus 2.9%; p = 0.7)....
EXCITE ISR: Excimer laser versus balloon angioplasty for stent restenosis of the superficial femoral
This multicenter, prospective, randomized trial compared the Excimer laser atherectomy (Excimer Laser Atherectomy = ELA, Spectranetics, Inc.) with a balloon angioplasty in patients with in-stent restenosis in the superficial femoral artery. The injury was greater than 4 cm and the reference vessel diameter 5 to 7 mm. The mean lesion length was 19 cm, and...
EVERBIO II: Bio-absorbable stent Absorb versus everolimus-eluting or biolimus stents
The new generation drug-eluting everolimus or biolimus stents have proved superior to the first generation. However, neo intimal proliferation and late thrombosis remains a problem not yet solved same for all drug-eluting stents. The Absorb (Abbott Vascular, Abbott Park, IL, USA) is the first absorbable vascular support approved for clinical use. The EVERBIO II study...
OPTIMIZE: 3 months versus 12 months of dual anti-aggregation with zotarolimus-eluting stents
The current recommendation for dual anti-aggregation post-DES implantation is 12 months. However, the ideal length for specific types of stents is unclear. This study aimed to evaluate the clinical non-inferiority at 3 months versus 12 months of dual anti-platelet therapy in patients undergoing coronary angioplasty with zotarolimus-eluting stents. The study randomized 1:1 to 3 months...
DESTINY TRIAL: Stent de hastes finas com polímero eluidor de sirolimus
Pedro Lemos2014-09-16
I-LOVE-IT2: Drug-eluting stents with a permanent polymer versus biodegradable in the same cobalt chromium platform
There is no strong evidence in the literature that the polymer type isolated (permanent or degradable) influences clinical outcomes after angioplasty and if the time of double anti-aggregation should be different with the degradable polymer. This work, with non-inferiority design, aimed to compare the sirolimus-eluting biodegradable polymer stent (Tivoli) versus the permanent polymer sirolimus-eluting stent...